Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Henry Q XiongJames L Abbruzzese

Abstract

To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in patients with epidermal growth factor receptor (EGFR)-expressing advanced pancreatic cancer. Patients with measurable locally advanced or metastatic pancreatic cancer who had never received chemotherapy for their advanced disease and had immunohistochemical evidence of EGFR expression were eligible for the multicenter phase II trial. Patients were treated with cetuximab at an initial dose of 400 mg/m(2), followed by 250 mg/m(2) weekly for 7 weeks. Gemcitabine was administered at 1,000 mg/m(2) for 7 weeks, followed by 1 week of rest. In subsequent cycles, cetuximab was administered weekly, and gemcitabine was administered weekly for 3 weeks every 4 weeks. Sixty-one patients were screened for EGFR expression, 58 patients (95%) had at least 1+ staining, and 41 were enrolled onto the trial. Five patients (12.2%) achieved a partial response, and 26 (63.4%) had stable disease. The median time to disease progression was 3.8 months, and the median overall survival duration was 7.1 months. One-year progression-free survival and overall survival rates were 12% and 31.7%, respectively. ...Continue Reading

References

Jan 1, 1992·The Journal of Pathology·N R LemoineW J Gullick
Apr 20, 1990·Cell·A Ullrich, J Schlessinger
Aug 18, 1993·Journal of the National Cancer Institute·J BaselgaJ Mendelsohn
Apr 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L RothenbergD D Von Hoff
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Jan 19, 2000·The American Journal of Gastroenterology·R H HawesJ L Abbruzzese
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaJ Mendelsohn
Jun 1, 2000·Investigational New Drugs·R A WolffJ L Abbruzzese
May 15, 2001·Endocrine-related Cancer·J Mendelsohn
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J Baselga
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V Craig Jordan, Monica Morrow
Jan 30, 2002·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael Thun
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstPatricia Mucci LoRusso
Nov 7, 2002·International Journal of Radiation Oncology, Biology, Physics·Donald J BuchsbaumKevin P Raisch
Feb 1, 2003·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Guido M SclabasPaul J Chiao
Feb 11, 2003·Seminars in Oncology·Daniel G Haller
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes

❮ Previous
Next ❯

Citations

Jan 31, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Weibo CaiXiaoyuan Chen
Sep 12, 2007·European Journal of Nuclear Medicine and Molecular Imaging·Weibo CaiXiaoyuan Chen
Jan 13, 2006·Cancer Chemotherapy and Pharmacology·J FeliuM González Barón
Jun 2, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mario E LacoutureUNKNOWN MASCC Skin Toxicity Study Group
Apr 23, 2008·Cancer Metastasis Reviews·Alexios StrimpakosKostas N Syrigos
Oct 23, 2012·Cancer Metastasis Reviews·Cindy NeuzilletEric Raymond
Aug 19, 2011·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Kimberley S SamkoeBrian W Pogue
Aug 15, 2006·Current Treatment Options in Oncology·Vicki L Keedy, Jordan Berlin
Mar 15, 2006·Current Gastroenterology Reports·Robert de W Marsh, Thomas George
Apr 26, 2005·Current Oncology Reports·Gregory Friberg, Hedy Lee Kindler
Apr 14, 2007·Current Oncology Reports·Hedy Lee Kindler
Sep 16, 2005·Current Treatment Options in Gastroenterology·Ralph H HrubanCharles J Yeo
Jun 9, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J L SotoA Carrato
Jan 10, 2013·Clinical Pharmacokinetics·Miroslav DostalekManoranjenni Chetty
Jan 8, 2008·The Lancet Oncology·Philip A Philip
Apr 1, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Shigeto UedaHidetaka Mochizuki
May 2, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Gustavo AlvarezHanlin L Wang
May 21, 2005·Nature Reviews. Cancer·Dan Laheru, Elizabeth M Jaffee
Jan 27, 2010·Nature Reviews. Clinical Oncology·Anastasios Stathis, Malcolm J Moore
Dec 12, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Joanne MorrisonLeonard W Seymour
Dec 14, 2011·The Pharmacogenomics Journal·S ParmarJ C Stingl
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
Sep 27, 2006·Cancer Biotherapy & Radiopharmaceuticals·Huguette Albrecht, Sally J DeNardo
Nov 8, 2007·Thyroid : Official Journal of the American Thyroid Association·Nathan A PennellThomas J Lynch
Mar 16, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y BalagulaM E Lacouture
Aug 30, 2008·British Medical Bulletin·S A DanoviN R Lemoine
Apr 6, 2006·Journal of the National Cancer Institute·Shinji TanakaShigeki Arii
Jun 29, 2011·Journal of the National Cancer Institute·Manish R SharmaMark J Ratain
Apr 18, 2008·Anti-cancer Drugs·Caio M Rocha-Lima
Jul 7, 2011·Anti-cancer Drugs·Hyunki KimEben L Rosenthal
Jun 5, 2007·Current Opinion in Oncology·Johanna Bendell, Richard M Goldberg
May 12, 2012·Journal of Immunotherapy·Eric LuedkeWilliam E Carson
May 10, 2011·American Journal of Clinical Oncology·Jaime R MerchanCaio M Rocha-Lima

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Hedy L KindlerEverett E Vokes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Leonard B SaltzRobert J Mayer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Malcolm J MooreNational Cancer Institute of Canada Clinical Trials Group
© 2022 Meta ULC. All rights reserved